Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Cogent Biosciences (COGT) EBITDA Margin (2017 - 2020)

Cogent Biosciences' EBITDA Margin history spans 4 years, with the latest figure at 16020.19% for Q3 2020.

  • Quarterly EBITDA Margin fell 1485127.0% to 16020.19% in Q3 2020 from the year-ago period, while the trailing twelve-month figure was 950.43% through Dec 2020, down 80899.0% year-over-year, with the annual reading at 950.43% for FY2020, 80899.0% down from the prior year.
  • EBITDA Margin came in at 16020.19% for Q3 2020, down from 1400.19% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 15.02% in Q4 2019 to a low of 16020.19% in Q3 2020.
  • The 4-year median for EBITDA Margin is 325.73% (2017), against an average of 1478.0%.
  • The largest YoY upside for EBITDA Margin was 29593bps in 2020 against a maximum downside of -1485127bps in 2020.
  • Cogent Biosciences' EBITDA Margin stood at 314.74% in 2017, then rose by 28bps to 225.86% in 2018, then surged by 107bps to 15.02% in 2019, then crashed by -106725bps to 16020.19% in 2020.
  • Per Business Quant, the three most recent readings for COGT's EBITDA Margin are 16020.19% (Q3 2020), 1400.19% (Q2 2020), and 86.67% (Q1 2020).